How did Neuren Pharmaceuticals (ASX:NEU) perform financially in 2025?

Neuren reported a strong full-year 2025, headlined by $65 million in royalty income, a 15% increase over the previous year. This growth was driven by its partner, Acadia Pharmaceuticals, recording US$391 million in net sales for DAYBUE (trofinetide).

What is the 2026 revenue guidance for Neuren Pharmaceuticals (ASX:NEU)?

Neuren expects to generate between $70 million and $77 million in royalty income during 2026. This is based on Acadia Pharmaceuticals’ net sales guidance for DAYBUE of US$460 million to US$490 million.

Why is the Q4 2025 patient data significant for Neuren (ASX:NEU) investors?

Neuren reached a record 1,070 unique patients receiving DAYBUE shipments in Q4 2025, indicating steady adoption of the treatment. Crucially, 76% of new prescriptions came from community physicians rather than specialised centres of excellence.

What new product launches could impact Neuren’s (ASX:NEU) 2026 performance?

The launch of DAYBUE STIX, a powder formulation approved by the FDA in late 2025, is a key catalyst for Q1 2026. This formulation is designed to improve patient adherence and attract families who previously declined or discontinued the original liquid version.

How does Neuren (ASX:NEU) make money from DAYBUE sales?

Neuren operates a capital-light model where it receives tiered royalty payments from its partner, Acadia Pharmaceuticals, which handles the commercialisation of DAYBUE. In 2025, this resulted in $65 million in high-margin cash flow for Neuren

What are the primary bull points for Neuren (ASX:NEU) after these results?

The "bull case" rests on accelerating quarterly growth (Q4 sales up 13% year-on-year) and a broadening prescriber base in the US. The introduction of a powder formulation (DAYBUE STIX) offers a clear path to higher patient retention.

What are the key risks or bear points for Neuren (ASX:NEU) shareholders?

A primary risk is the heavy concentration of revenue on a single product, DAYBUE, in a single primary market (the US). While 2026 guidance is higher, any plateau in patient uptake or safety concerns could lead to a valuation re-rating.

Is Neuren Pharmaceuticals (ASX:NEU) profitable following the 2025 results?

While the report focuses on "strong financial results" and A$65 million in royalty income, it confirms a strengthening financial position rather than detailing a final NPAT.

Image for illustrative purposes only. Not a real photo.

Neuren Pharmaceuticals shares steady as DAYBUE sales drive growth

Written by Jon CuthbertPublished Feb 26, 2026, 3:01 AMLast Updated Jul 6, 2026, 1:00 PM

Melbourne-based Neuren Pharmaceuticals (ASX:NEU) announced strong financial results for the full year 2025, driven by the continued commercial success of DAYBUE (trofinetide) in the United States.

Neuren's partner, Acadia Pharmaceuticals, reported full-year DAYBUE net sales of US$391 million, representing a 12% year-on-year increase and meeting prior guidance.

Growth accelerated in the final quarter, with Q4 sales reaching a record US$110 million, up 13% against the previous corresponding period.

This commercial momentum translated into returns for Neuren, which earned $65 million in royalty income for 2025, a 15% increase over 2024.

The final quarter contributed $20 million to this total, marking a 21% increase over the third quarter of 2025.

Patient uptake also reached new heights, with a record 1,070 unique patients receiving shipments in Q4.

76% of new prescriptions originated from community physicians, signalling broad market adoption beyond specialised centres of excellence.

Acadia has provided 2026 net sales guidance of US$460–490 million, which is expected to generate $70–$77 million in royalties for Neuren.

The outlook excludes potential EU sales and is bolstered by the Q1 2026 launch of DAYBUE STIX, a new powder formulation approved by the FDA in December 2025.

Neuren CEO Jon Pilcher noted that this sustained growth strengthens the company’s financial position.At the time of reporting, Neuren Pharmaceuticals' share price was $13.55.

Neuren Pharmaceuticals shares steady as DAYBUE sales drive growth

Perguntas frequentes

Ativos relacionados a notícia